Drug Trial Radar · NCT01580007
Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB)
Last checked: Nov 19, 2026Latest source record: Feb 13, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
288
Actual
Start
Dec 2010
Primary completion
Dec 2014
Study completion Dec 2014
Sponsor
- Lead sponsor
- International Centre for Diarrhoeal Disease Research, BangladeshAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Karolinska Institutet; National Institute of Diseases of the Chest and Hospital, Bangladesh; University of Iceland
- First posted
- Apr 18, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Vitamin D exerts its effects via the Vitamin D Receptor (VDR) present in activated macrophages and induces expression and release of the cathelicidin, LL-37, a human antimicrobial peptide involved in killing of MTB. We aimed to investigate whether treatment of newly diagnosed pulmonary TB patients for 2 months with adjunctive PBA and vitamin D (Cholecalciferol) in combination with standard DOTS therapy (i) can improve response to standard short course TB therapy towards a rapid recovery; (ii) can induce expression of LL-37 in macrophages; (iii) can enhance killing capacity of macrophages isolated from TB patients infected in vitro with MTB; and (iv) does not evoke any adverse effects.
Conditions
- Pulmonary Tuberculosis
Interventions
Active Sodium Phenylbutyrate and active cholecalciferolDrug
Sodium Phenylbutyrate: 500 mg twice daily orally for 2 months Cholecalciferol: 5000 IU once daily orally for 2 months
Placebo Sodium Phenylbutyrate plus active cholecalciferolDrug
Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Cholecalciferol: 5000 IU once daily for 2 months
Active Sodium Phenylbutyrate and placebo cholecalciferolDrug
Sodium phenylbutyrate: 500 mg twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
Placebo Sodium Phenylbutyrate plus placebo cholecalciferolDrug
Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of pulmonary TB patients who are culture negative in sputum in week 4Time frame: week 4
- Difference in improvement in clinical endpoints consisting of cough clearance, percentage chest x-ray clearance, fever remission and weight increase upto 8 weeks.Time frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institute of Diseases of Chest and Hospital (NIDCH)
Dhaka, Bangladesh
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.